NCT01682044 2017-10-09
Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma
Roswell Park Cancer Institute
Phase 2 Completed
Roswell Park Cancer Institute
Memorial Sloan Kettering Cancer Center